



ASX release

24 July 2008

## **US \$1.6m new pharmaceutical trials contracts**

### ***US \$2.8m to pharma in past 60 days***

AtCor Medical (ASX:ACG), the developer and marketer of the SphygmoCor<sup>®</sup> system which measures central blood pressures and arterial stiffness non-invasively, today announced that it has signed two new agreements to supply SphygmoCor<sup>®</sup> systems and clinical trial support services to a leading international pharmaceutical company. The minimum total value of these contracts is USD\$1.6 million, the majority of which will be recognised in the current financial year. These new orders bring the minimum total value of pharmaceutical trial contracts secured by AtCor over the past 60 days to over US \$2.8 million.

Duncan Ross, CEO of AtCor Medical said “Our pharmaceutical sales continue to grow and over the past two months we have executed significant new contracts in the US and Europe. This demonstrates the increasing importance of SphygmoCor as a tool for understanding drug efficacy and mechanisms of action. We look forward to continuing to build mutually beneficial relationships with our growing list of pharmaceutical trial customers.”

Mr. Ross added, “The growing use of SphygmoCor systems in clinical trials and increasing volume of publications concerning central blood pressures and arterial stiffness indicate a move toward establishing a new standard for cardiovascular risk assessment and management.”

### **About AtCor Medical**

AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease. Its technology allows researchers and clinicians to assess central blood pressure non-invasively. The company’s SphygmoCor<sup>®</sup> system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave, effects which cannot be detected with standard blood pressure monitoring. More than 1,400 SphygmoCor<sup>®</sup> systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies, and the company’s technology have been featured in over 200 peer-reviewed studies published in leading medical journals. AtCor has operations in Australia, the United States, and Europe. For further information, please visit our web site at [www.atcormedical.com](http://www.atcormedical.com)

*For further information, please contact:*

Duncan Ross – AtCor Medical CEO  
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO  
+61 (2) 9874 8761

*Media enquiries to:*

Ashley Rambukwella – Financial &  
Corporate Relations  
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)

---

SphygmoCor<sup>®</sup> is a registered trademark of AtCor Medical Pty Ltd and its related entities.